CD274 and non-small cell lung carcinoma: In the KEYNOTE-042 study, evaluating the efficacy of pembrolizumab in treatment-naive patients with NSCLC with PD-L1 expression–positive tumor, the duration of response did not differ according to PD-L1 expression levels (PD-L1 tumor proportion score [TPS] 1%–49% versus ≥50%), whereas overall survival (OS) in patients with PD-L1 high expression was better compared with those with PD-L1 low expression.8